FORM	4
------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
1. Name and Address of Reporting Person <sup>*</sup> Whitehead Warren	2. Issuer Name and Aptose Biosciene				l	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director10% Owner				
(Last) (First) C/O APTOSE BIOSCIENCES INC CONSUMERS ROAD, SUITE 110	3. Date of Earliest Tr 06/23/2020	ransaction (	Montl	h/Day/Yea	ar)	Officer (give title below)O	ther (specify belo	ow)		
(Street) TORONTO, A6 M2J 4R3	4. If Amendment, Da	ate Original	Filed	(Month/Day/	Year)	6. Individual or Joint/Group Filing(Chec _X_Form filed by One Reporting Person Form filed by More than One Reporting Perso		ne)		
(City) (State)	(Zip)		Table I - N	on-D	erivative	Securit	ties Acqui	ired, Disposed of, or Beneficially Own	ned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transact Code (Instr. 8)	tion	4. Securi (A) or D (Instr. 3,	isposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial
		(Monul/Day/ Fear)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	or Indirect (D) or Indirect (I) (Instr. 4)	
Common Shares	06/23/2020		М		1,250	А	\$ 1.91 (1)	51,250	D	
Common Shares	06/23/2020		М		500	А	\$ 1.6 (2)	51,750	D	
Common Shares	06/23/2020		М		1,250	А	\$ 4.22 ( <u>3</u> )	53,000	D	
Common Shares	06/23/2020		М		10,000	А	\$ 1.12 ( <u>4</u> )	63,000	D	
Common Shares	06/23/2020		S		13,000	D	\$ 7.08 (7)	50,000	D	
Common Shares	06/23/2020		S		5,000	D	\$ 7.17 (8)	45,000	D	
Common Shares	06/24/2020		М		5,000	А	\$ 1.02 (5)	50,000	D	
Common Shares	06/24/2020		М		7,000	А	\$ 2.6 (6)	57,000	D	
Common Shares	06/24/2020		S		12,000	D	\$ 6.73 (9)	45,000	D	
Common Shares	06/24/2020		S		5,000	D	\$ 6.78 (10)	40,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II	Derivative Securities Acquired, Disposed of, or Beneficially Own	ed
	(a g puts calls warrants options convertible securities)	

(e.g., puts, cans, warrants, options, convertible securities)														
2.	3. Transaction	3A. Deemed	4.		5. Numbe	er	6. Date Exerci	sable and	7. Title and	Amount	8. Price of	9. Number of	10.	11. Nature
Conversion	Date	Execution Date, if	Transact	tion	of Deriva	tive	Expiration Dat	e	of Underlyin	ıg	Derivative	Derivative	Ownership	of Indirect
or Exercise	(Month/Day/Year)	any	Code		Securities	s	(Month/Day/Y	ear)	Securities		Security	Securities	Form of	Beneficial
Price of		(Month/Day/Year)	(Instr. 8)	)	Acquired	(A)			(Instr. 3 and	4)	(Instr. 5)	Beneficially	Derivative	Ownership
Derivative					or Dispos	sed						Owned	Security:	(Instr. 4)
Security					of (D)							Following	Direct (D)	
					(Instr. 3,	4,						Reported	or Indirect	
					and 5)							· · ·	· · /	
												(Instr. 4)	(Instr. 4)	
							Date	Expiration		-				
							Exercisable	Date						
			Cada	v	(A)					-				
			Code	v	(A)	(D)				Shares				
¢ 1 01 (1)	06/22/2020		м		1 250		11/20/2011	11/20/2021	Common	1 250	\$ 0	0	D	
\$ 1.91	00/23/2020		IVI		1,230		11/29/2011	11/29/2021	Shares	1,230	\$0	0	D	
	Conversion or Exercise Price of Derivative Security	Conversion Date or Exercise (Month/Day/Year) Price of Derivative Security	Conversion or Exercise Price of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year)   Image: Conversion of the security Image: Conversion of the security Image: Conversion of the security   Image: Conversion of the security Image: Conversion of the security Image: Conversion of the security   Image: Conversion of the security Image: Conversion of the security Image: Conversion of the security   Image: Conversion of the security Image: Conversion of the security Image: Conversion of the security   Image: Conversion of the security Image: Conversion of the security Image: Conversion of the security   Image: Conversion of the security Image: Conversion of the security Image: Conversion of the security   Image: Conversion of the security Image: Conversion of the security Image: Conversion of the security   Image: Conversion of the security Image: Conversion of the security Image: Conversion of the security   Image: Conversion of the security Image: Conversion of the security Image: Conversion of the security   Image: Conversion of the security Image: Conversion of the security Image: Conversion of the security   Image: Conversion of the security Image: Conversion of the security Image: Conversion of the security   Image: Conv	2. 3. Transaction Conversion or Exercise Price of Derivative Security 2. 3. Transaction (Month/Day/Year) (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) Code Code Code	2. 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if Price of Derivative Security 2 Code (Instr. 8)	2. 3. Transaction Conversion or Exercise Price of Derivative Security 2. 3. Transaction Date (Month/Day/Year) Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Instr. 3) and 5) Code V (A)	2. 3. Transaction Date 3A. Deemed Execution Date, if Ore in the integration or Exercise (Month/Day/Year) 5. Number of Derivative Securities (Month/Day/Year)   Price of Derivative Security (Month/Day/Year) (Month/Day/Year) (Instr. 8) 5. Number of Derivative Securities (Instr. 8)   Security Code V (A. (Instr. 3, 4, and 5)	2. 3. Transaction Date 3.A. Deemed Execution Date, if or Exercise 4. 5. Number of Derivative (Month/Day/Year) 6. Date Exerci Expiration Date, (Month/Day/Year)   9 0. 0.0 0.0 0.0   9 0.0 0.0 0.0 0.0 0.0   10 0.0 0.0 0.0 0.0 0.0 0.0   10 0.0 0.0 0.0 0.0 0.0 0.0 0.0   10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   10 0.0	2. 3. Transaction Date 3.A. Deemed 4. 5. Number of Derivative 6. Date Exercisable and Execution Date, if any   Price of Derivative Security (Month/Day/Year) (Month/Day/Year) 4. 5. Number of Derivative (Instr. 8) 6. Date Exercisable and Expiration Date (Month/Day/Year)   Image: Conversion of Exercise Price of Derivative Security 6. Date Exercisable and Expiration Date (Month/Day/Year)   Image: Conversion of Exercise Price of Derivative Security 6. Date Exercisable and Expiration Date (Month/Day/Year)   Image: Conversion of Exercise Price of Derivative Security Image: Conversion of	2. 3. Transaction Date 3A. Deemed Execution Date, if any (Month/Day/Year) 4. 5. Number of Derivative Securities 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and of Underlyin Securities   2. Conversion or Exercise (Month/Day/Year) 4. 5. Number of Derivative Securities 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and of Underlyin Securities   2. (Month/Day/Year) (Month/Day/Year) 4. 5. Number of Derivative Securities 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and of Underlyin Securities   2. (Month/Day/Year) (Instr. 8) 5. Number of Derivative Securities 6. Date Exercisable and Expiration Date 7. Title and of Underlyin Securities   2. (Month/Day/Year) (Instr. 3, 4, and 5) Date Expiration Date Title   3. 06/23/2020 M 1.250 1.1/29/2011 1.1/29/2021 Common	2. 3. Transaction Date 3. Loemed Execution Date, if or Exercise 4. 5. Number of Derivative Securities 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Underlying Securities   Price of Derivative Security (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 5. Number of Derivative (Instr. 8) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Underlying Securities   Security (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 5. Number of Derivative Securities 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Underlying Securities   Security (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 5. Number of (D) (Instr. 3, 4, and 5) 6. Date Exercisable Title and Amount of Underlying Securities   Security (Month/Day/Year) (Month/Day/Year) Date (Instr. 3, 4, and 5) Title Amount or Number of Shares   Security (Month/Day/Year) (A) (D) Date (Instr. 3) Expiration Date Title Amount or Number of Shares	2. 3. Transaction Date 3. Deemed Execution Date, if or Exercise 4. 5. Number of Derivative Securities 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Securities   Security (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 5. Number of Derivative Securities 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Securities   Security (Month/Day/Year) (Month/Day/Year) 0. Date (Instr. 3, 4, and 5) Date Expiration Date 7. Title and Amount of Underlying Securities 8. Price of Derivative Securities   Security (Month/Day/Year) (Instr. 3, 4, and 5) Date Expiration Date 7. Title and Amount of Underlying 8. Price of Derivative Securities   Security (Instr. 3, 4, and 5) (Instr. 3, 4, and 5) Date Expiration Date Title Amount of Shares   Security (Instr. 3, 4, and 5) (Instr. 3, 4, and 5) Int/29/2011 I1/29/2021 Common 1.250 \$.0	2. 3. Transaction Date 3. Loemed 4. 5. Number of Derivative 6. Date Exercisable and of Derivative 7. Title and Amount of Underlying Securities 8. Price of Derivative 9. Number of Derivative   Security (Month/Day/Year) (Month/Day/Year) 4. 5. Number Transaction Code (Instr. 8) 6. Date Exercisable and Derivative 7. Title and Amount of Underlying Securities 8. Price of Derivative 9. Number of Derivative   Security (Month/Day/Year) (Month/Day/Year) 4. 5. Number of Derivative 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Underlying Securities 8. Price of Derivative 9. Number of Derivative   Security (Month/Day/Year) 4. 5. 9. 1.	2. 3. Transaction Date 3. Transaction Date 3. Deemed Execution Date, if any 4. 5. Number of Derivative Securities 6. Date Exercisable and Expiration Date 7. Title and Amount of Underlying Securities 8. Price of Derivative Securities 9. Number of Derivative Securities 10.   Security (Month/Day/Year) (Month/Day/Year) (Instr. 8) 5. Number of Derivative Securities 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Underlying Securities 8. Price of Derivative Securities 9. Number of Derivative Securities 10.   Security (Month/Day/Year) (Instr. 8) 5. Number of Derivative 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Underlying Securities 8. Price of Derivative Security 9. Number of Derivative Security 10.   Security (Instr. 3) 4. 5. 5. Number of (D) 6. Date Exercisable 7. Title and Amount (Instr. 3 and 4) 8. Price of Derivative 9. Number Securities 10.   Security Code V (A) Date Exercisable Feptie 7. Title and Amount (Instr. 3) 8. Price of Securities 9. Number of Undirect 10.   Security Code V (A) Date Expiration Date <td< td=""></td<>

Director Stock Option (Right to Buy)	\$ 1.6 <sup>(2)</sup>	06/23/2020	М	500	03/09/2012	03/09/2022	Common Shares	500	\$ 0	0	D	
Director Stock Option (Right to Buy)	\$ 4.22 <sup>(3)</sup>	06/23/2020	М	1,250	11/29/2011	11/29/2021	Common Shares	1,250	\$ 0	0	D	
Director Stock Option (Right to Buy)	\$ 1.12 <sup>(4)</sup>	06/23/2020	М	10,000	03/28/2017	03/28/2027	Common Shares	10,000	\$ 0	0	D	
Director Stock Option (Right to Buy)	\$ 1.02 <sup>(5)</sup>	06/24/2020	М	5,000	06/06/2017	06/06/2027	Common Shares	5,000	\$ 0	0	D	
Director Stock Option (Right to Buy)	\$ 2.6 <u>(6)</u>	06/24/2020	М	7,000	01/19/2018	01/19/2028	Common Shares	7,000	\$ 0	53,000	D	

## **Reporting Owners**

	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
Whitehead Warren C/O APTOSE BIOSCIENCES INC. 251 CONSUMERS ROAD, SUITE 1105 TORONTO, A6 M2J 4R3	Х								

# Signatures

rate of 1.3516.

/s/ Gregory K. Chow as attorney-in-fact for Warren Whitehead	06/25/2020
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Converted from Canadian exercise price of \$2.58 using an exchange rate of 1.3516.
- (2) Converted from Canadian exercise price of \$2.16 using an exchange rate of 1.3516.
- (3) Converted from Canadian exercise price of \$5.70 using an exchange rate of 1.3516.
- (4) Converted from Canadian exercise price of \$1.52 using an exchange rate of 1.3516.
- (5) Converted from Canadian exercise price of \$1.38 using an exchange rate of 1.3516.
- (6) Converted from Canadian exercise price of \$3.52 using an exchange rate of 1.3516.
- The sale price of \$7.08 is a weighted average price. These shares were sold in multiple transactions at prices ranging from C\$9.55 to C\$9.6464, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the rages set forth in this footnote (7). The average weighted sale price of C\$9.57 was converted into U.S. dollars using an exchange
- (8) Converted from Canadian sale price of \$9.69 using an exchange rate of 1.3516.
- The sale price of \$6.73 is a weighted average price. These shares were sold in multiple transactions at prices ranging from C\$9.00 to C\$9.22, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the
- (9) provide to Aprose biosciences inc., any security notice of Aprose biosciences inc., of the start of the securities and Exchange Commission, upon request, this information regarding the number of shares sold at each separate price within the rages set forth in this footnote (9). The Canadian average weighted sale price of \$9.09 was converted to U.S. dollars using an exchange rate of 1.3516.
- (10) Converted from Canadian sales price of \$9.1678 using an exchange rate of 1.3516.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.